Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion criteria:~* Participants with primary hypercholesterolemia receiving a lipid-lowering treatment other than atorvastatin or not at stable dose of atorvastatin 10 mg, 20 mg, or 40 mg for at least 6 weeks prior to screening period or drug naive participants if they are likely to have low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL (≥ 2.59 mmol/L) at the end of the 6-week run-in treatment period on atorvastatin therapy~OR~* Participants with primary hypercholesterolemia treated with atorvastatin at stable dose of 10 mg, 20 mg, or 40 mg for at least 6 weeks prior to screening period and likely to have LDL-C ≥ 100 mg/dL (≥ 2.59 mmol/L) at the screening visit~Exclusion criteria:~1. LDL-C \< 100 mg/dL (\< 2.59 mmol/L):~   * After the run-in period on atorvastatin (10 mg, 20 mg, or 40 mg) for participants receiving a lipid-lowering treatment other than atorvastatin or not at stable dose of atorvastatin 10 mg, 20 mg, or 40 mg for at least 6 weeks prior to the screening, or drug naive participant~   OR~  * At the first visit for participants who were being treated with stable dose of atorvastatin (10 mg, 20 mg, or 40 mg) for at least 6 weeks prior to screening~2. Participants not previously instructed on a cholesterol-lowering diet~3. Participants with type 1 diabetes~4. Participants with type 2 diabetes treated with insulin~5. Participants with type 2 diabetes and with an glycated hemoglobin (HbA1c) ≥ 8.5% at screening visit (considered poorly controlled)~6. Laboratory findings measured before randomization:~   * Triglycerides (TG) \> 350 mg/dL (\> 3.95 mmol/L) at screening visit~  * Positive serum or urine pregnancy test in females of childbearing potential~7. Pregnant or breast-feeding women~8. Women of childbearing potential with no effective contraceptive method~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
- Alirocumab 50 mg Q2W (Type: EXPERIMENTAL): Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
- Alirocumab 100 mg Q2W (Type: EXPERIMENTAL): Alirocumab 100 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
- Alirocumab 150 mg Q2W (Type: EXPERIMENTAL): Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
- Alirocumab 200 mg Q4W (Type: EXPERIMENTAL): Alirocumab 200 mg every 4 weeks (Q4W) and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
- Alirocumab 300 mg Q4W (Type: EXPERIMENTAL): Alirocumab 300 mg Q4W and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).